China Vanke Co.,Ltd.
000002
Merit Interactive
300766
Zhejiang Orient Financial Holdings Group
600120
4
Cambricon
688256
5
Zhuhai Huajin Capital
000532
CN Stock MarketDetailed Quotes
002873 Guiyang Xintian Pharmaceutical
- 9.28
- +0.06+0.65%
Market Closed Jan 27 15:00 CST
2.27BMarket Cap41.80P/E (TTM)
9.43High9.21Low20.69KlotVolume9.27Open9.22Pre Close19.29MTurnover0.87%Turnover Ratio28.04P/E (Static)244.10MShares14.2352wk High2.31P/B2.22BFloat Cap7.4552wk Low10.14Limit Up238.78MShs Float19.83Historical High8.30Limit Down2.39%Amplitude6.14Historical Low0.11Dividend TTM9.32Avg Price11.12KlotAsk1.19%Div YieldTTM100Lot Size9.16KlotBid
Guiyang Xintian Pharmaceutical News
Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms a
Xintian Pharmaceutical (002873): Short-term performance is under pressure, marketing system reform is beginning to bear fruit
Xintian Pharmaceutical (002873): Performance under phased pressure continues to consolidate core competitiveness and unleash growth potential
China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is
Xintian Pharmaceutical (002873): Proposed acquisition of Huilun Pharmaceutical to deepen the small molecule chemical sector layout and continue to consolidate core competitiveness and unleash growth potential
Xintian Pharmaceutical (002873) Company Information Update Report: Proposed acquisition of Huilun Pharmaceutical to further expand the commercial footprint of small molecule chemicals
Xintian Pharmaceutical (002873): Consolidating the Advantages and Diversification of Gynecology/Urology Segments and Exploiting Growth Curves
Xintian Pharmaceutical (002873): Innovation Drives Endogenous Growth, OTC Channels Accelerate National Deployment
Xintian Pharmaceutical (002873): Brand plans to promote national new product follow-up and reserve future momentum
Xintian Pharmaceutical (002873): The performance of overcoming the epidemic is in line with expectations, and the promotion of R&D channels can be expected in the future
Xintian Pharmaceutical (002873) Company Information Update Report: Performance Meets Expectations, Channel Expansion Continues to Advance into the Fast Track of Development
Xintian Pharmaceutical (002873): Resilient under the influence of the epidemic in 2022, and high growth is expected to resume in 2023
Xintian Pharmaceutical (002873): Focus on the development and layout of traditional Chinese medicine to maintain steady growth
Xintian Pharmaceutical (002873): Performance is in line with expectations, growth rate is expected to gradually increase in the second half of the year
Xintian Pharmaceutical (002873): Resilient brand plans are beginning to bear fruit under the influence of the pandemic
Xintian Pharmaceutical (002873): The field of multiple diseases is making comprehensive efforts to overcome the steady growth of the epidemic
Xintian Pharmaceutical (002873) Company Brief Review Report: Core Varieties Entered the Rapid Release Stage, OTC Channel Expansion Opens Up Room for Growth
Xintian Pharmaceutical (002873) Company Information Update Report: Q1 performance is in line with expected revenue, profit growth is expected to gradually increase
Xintian Pharmaceutical (002873): Short-term performance is under pressure, the original intention is firm and the goal continues to move forward throughout the year
Xintian Pharmaceutical (002873): Innovative proprietary Chinese medicine enterprise focusing on gynaecology and urological characteristics